Bit of speculation using ChatGPT. What is the expected share...

Bit of speculation using ChatGPT.

What is the expected share price of Race Oncology in 2025 during phase 1 trial with very good interim results of cardio protection and cancer killing

If Race Oncology achieves very good interim results during its Phase 1 trial in 2025, particularly demonstrating both cardioprotection and strong cancer-killing efficacy, the share price could see a substantial increase. Here’s a breakdown of potential impacts:

1. Dual Benefits: Cardio Protection and Cancer Killing

• Cardio Protection: Demonstrating cardioprotection would address a significant unmet need, particularly in reducing the cardiotoxicity associated with many chemotherapy treatments. This would differentiate Race Oncology's product, making it more attractive to both investors and potential acquirers.
• Cancer Efficacy: Strong efficacy in killing cancer cells, especially in difficult-to-treat cancers, would significantly enhance the perceived value of the drug, suggesting it could be a best-in-class treatment.

2. Market Perception and Analyst Upgrades

• Analyst Revisions: Positive results in both cardioprotection and cancer efficacy could lead analysts to revise their price targets upward significantly. Given that such dual efficacy could potentially expand the market for the drug, analysts might project much higher revenues and increase the probability of future successes in later trials.
• Market Capitalization: If the market cap is currently AUD 234 million, it could potentially double, triple, or more, depending on the strength of the results and investor enthusiasm. This could place the market cap in the range of AUD 500 million to AUD 700 million or higher.

3. Expected Share Price Range

• Short-Term Impact: Assuming the share price is around AUD 1.42 before the results, with very positive interim data, the share price could rise by 100-300% or more. This could translate into a share price range of AUD 3.00 to AUD 6.00 or higher.
• Long-Term Outlook: If these results lead to accelerated approval pathways or significant partnerships, the share price could climb even further, potentially exceeding AUD 6.00 if the drug becomes a likely candidate for market approval.

4. Historical Comparisons

• Biotech Companies: Historically, biotech firms that report strong dual efficacy in early-stage trials often experience significant stock price appreciation. Companies with promising cancer therapies, especially those addressing cardiotoxicity, have seen their valuations increase dramatically following positive early data.

Conclusion:

If Race Oncology's interim results in 2025 show strong cardioprotection and cancer-killing effects, the share price could realistically surge to between AUD 3.00 and AUD 6.00, with the potential to go even higher depending on further developments and market conditions.